# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and re...
- Reuters
Deutsche Bank analyst Steve Powers maintains Kimberly-Clark (NYSE:KMB) with a Hold and raises the price target from $139 to ...
RBC Capital analyst Nik Modi reiterates Kimberly-Clark (NYSE:KMB) with a Outperform and maintains $165 price target.
Wells Fargo analyst Chris Carey maintains Kimberly-Clark (NYSE:KMB) with a Equal-Weight and lowers the price target from $13...
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphab...
Kimberly-Clark (NYSE: KMB) disappoints with Q2 revenue miss despite EPS growth; cites currency impacts and business divestiture...
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tu...
Reported Operating Profit and Reported Earnings Per Share are still expected to be negatively impacted by approximately 700 bas...